Given the seminal discovery of the critical and non-redundant immunosuppressive role of A2AR (24) and the therapeutic potential of A2AR blockade for T cell–based immunotherapy (25), our study demonstrates a viable strategy by targeting A2AR in combination with inhibition of lipid peroxidation to improve persistence and functionality of ACT against cancer. The gene discussed is ADORA2A; the disease is cancer.